Compounds > docloxythepin
Page last updated: 2024-11-07

docloxythepin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

docloxythepin: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151604
CHEMBL ID3246256
MeSH IDM0071768

Synonyms (12)

Synonym
docloxythepin
4-(2-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-1-piperazineethanol
1-piperazineethanol, 4-(2-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-
vufb-10032
brn 0900422
2-[4-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-6-yl)piperazin-1-yl]ethanol
56934-18-0
CHEMBL3246256
2-[4-(2-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-1-piperazinyl]ethanol
AE-641/00771014
DTXSID60972375
2-[4-(2-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)piperazin-1-yl]ethan-1-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1136386Toxicity in ip dosed Sprague-Dawley rat assessed as induction of maximum catalepsy1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
AID1136384Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as dose required to decrease the continuous (Sidman) lever-pressing response to <50%1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
AID1136382Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as inhibition of amphetamine-induced stereotyped behaviour administered 15 mins after d-amphetamine challenge1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
AID1136383Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as conditioned active avoidance failure after 30 mins1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
AID1136385Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as protection against epinephrine-induced mortality administered 1 hr prior to epinephrine injection1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
octoclothepine
octoclothepine: major tranquilizer with action similar to those of the phenothiazines; used in schizophrenic & manic psychoses; minor decriptor (77-86); on-line & INDEX MEDICUS search DIBENZOTHIEPINS (77-86); RN given refers to parent cpd without isomeric designation		2.3620dibenzothiepine
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		1.9510dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
dothiepin hydrochloride
Dothiepin: A tricyclic antidepressant with some tranquilizing action.		1.9510dothiepin
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		1.9510benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Anochlesia
[description not available]		01.9510